Lung Cancer clinical trials in Arkansas

29 actively recruiting lung cancer trials at 7 sites across Arkansas.

Data from ClinicalTrials.gov · last refreshed 2026-08-17

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03851445

Sites in Arkansas:

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
University of Arkansas for Medical Sciences — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04267848

Sites in Arkansas:

Mercy Hospital Fort Smith — Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04181060

Sites in Arkansas:

Mercy Hospital Fort Smith — Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology

NCT ID: NCT05624996

Sites in Arkansas:

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
University of Arkansas for Medical Sciences — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting NIH

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of …

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04402788

Sites in Arkansas:

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06096844

Sites in Arkansas:

Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
Mercy Hospital Fort Smith — Fort Smith, Arkansas
Highlands Oncology Group - Rogers — Rogers, Arkansas
Highlands Oncology Group — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology

NCT ID: NCT06500455

Sites in Arkansas:

Mercy Hospital Fort Smith — Fort Smith, Arkansas
University of Arkansas for Medical Sciences — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…

Sponsor: Children's Oncology Group

NCT ID: NCT05235165

Sites in Arkansas:

Arkansas Children's Hospital — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer

NCT ID: NCT07144280

Sites in Arkansas:

Highlands Oncology Group, PA — Fayetteville, Arkansas
Highlands Oncology Group, PA — Rogers, Arkansas
Highlands Oncology Group, PA — Springdale, Arkansas
Highlands Oncology Group — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Sponsor: Summit Therapeutics

NCT ID: NCT06767514

Sites in Arkansas:

Clinical Study Site — Hot Springs, Arkansas
Clinical Study Sites — Jonesboro, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca

NCT ID: NCT06357533

Sites in Arkansas:

Research Site — Little Rock, Arkansas
Research Site — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology

NCT ID: NCT06500481

Sites in Arkansas:

University of Arkansas for Medical Sciences — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…

Sponsor: Mirati Therapeutics Inc.

NCT ID: NCT06875310

Sites in Arkansas:

Local Institution - 0686 — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06312137

Sites in Arkansas:

UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060) — Little Rock, Arkansas
Highlands Oncology Group-Research Department ( Site 0062) — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…

Sponsor: Bristol-Myers Squibb

NCT ID: NCT07063745

Sites in Arkansas:

Highlands Oncology Group — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Sponsor: AstraZeneca

NCT ID: NCT06417814

Sites in Arkansas:

Research Site — Fayetteville, Arkansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…

Sponsor: ImmunityBio, Inc.

NCT ID: NCT06745908

Sites in Arkansas:

Highlands Oncology Group — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05642572

Sites in Arkansas:

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
University of Arkansas for Medical Sciences — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT06031688

Sites in Arkansas:

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
University of Arkansas for Medical Sciences — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT06116682

Sites in Arkansas:

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
University of Arkansas for Medical Sciences — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT07293247

Sites in Arkansas:

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie

NCT ID: NCT06568939

Sites in Arkansas:

University of Arkansas for Medical Sciences /ID# 272923 — Little Rock, Arkansas

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

NCT ID: NCT04389632

Sites in Arkansas:

Highlands Oncology Group — Fayetteville, Arkansas
Highlands Oncology Group — Rogers, Arkansas
Highlands Oncology Group — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…

Sponsor: Pfizer

NCT ID: NCT05538130

Sites in Arkansas:

Highlands Oncology Group, PA — Fayetteville, Arkansas
Highlands Oncology Group, PA — Rogers, Arkansas
Highlands Oncology Group, PA — Springdale, Arkansas

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …

Sponsor: Pfizer

NCT ID: NCT05355701

Sites in Arkansas:

Highlands Oncology Group, PA — Fayetteville, Arkansas
Highlands Oncology Group, PA — Rogers, Arkansas
Highlands Oncology Group, PA — Springdale, Arkansas

View on ClinicalTrials.gov →

Showing 25 of 29 trials with sites in Arkansas. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17